Table 1.
Sample characteristics. M4M51 and M4M53 were derived from different samples of the same patient. * Information taken from https://www.cellosaurus.org/search (accessed on 5 January 2023). † Histologically not typical for GCTB. ‡ Some of the samples were of poor quality for de-termining regression rates after PDT and were therefore not considered for analysis, which explains the delta compared to evaluable samples in PDD. n.a. = Not applicable; n.d. = Not defined.
| ID | Entitity | Age | Sex | Grade | Sample Origin | Pretreatment | Inoculated Eggs |
Loss (Egg Death) | Contaminated Eggs | No Visible Tumor | Evaluable Grafts (PDD) |
Loss (Death after PDT) | Evaluable Grafts (PDT) |
Confirmed Histology |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CHOR-SN1 | Chordoma | 53 | m | n.a. | resection, Os sacrum; metachronous lymphnodular, osseous and pulmonary metastases | radiotherapy, Imatinib, Sirolimus, Sorafenib, debulking | 4 | 0 | 0 | 0 | 4 | n.d. | n.d. | 3 |
| E0R4 | GCTB | 45 | m | n.a. | curettage, proximal tibia | none | 11 | 0 | 1 | 1 | 9 | n.d. | n.d. | (7) † |
| E5K5 | Osteosarcoma | 20 | m | TNM: cT3 N0 M0 G high-grade | resection of primary site, proximal femur | 2× Doxorubicin/Cisplatin, 3× MTX | 12 | 1 | 0 | 0 | 11 | 2 | 8 ‡ | 10 |
| ESS-SN1 | Endometrial Stromal Sarcoma | 19 | f | TNM: T4 Nx M1 (OTH, PER) Stage: IV (UICC 2016 [8th Edition]) high-grade |
palliative resection, middle and lower abdomen | 3× Ifosfamid/Doxorubicin | 10 | 0 | 6 | 0 | 7 | 0 | 7 | 7 |
| GISTa-SN1 | GIST | 67 | m | TNM (initial): pT4 cN0 cM0; current: Tx Nx M1 Stage (initial): IIIb (UICC 2016 [8th Edition]); current: Stage IV |
resection of metastasis, right abdominal wall | laparotomy, BLU285 | 5 | 1 | 0 | 0 | 4 | n.d. | n.d. | n.d. |
| H7L6 | Synovialsarcoma | 20 | f | TNM: pT1 L0 V0 Pn0 R0 (UICC 2017 [8th Edition]) Stage: FNCLCC-Grading: 3 + 1 + 0 = 4 (G2) |
resection, proximal upper arm | none | 8 | 0 | 5 | 0 | 3 | n.d. | n.d. | n.d. |
| H7N5 | Chondrosarcoma | 53 | f | TNM: pT1 L0 V0 Pn0 R0 (UICC 2017 [8th Edition]) | resection, lateral distal thigh | none | 23 (PDXs) | 5 | 6 | 0 | 12 (PDXs) | n.d. | n.d. | n.d. |
| 13 (CDXs) | 2 | 2 | 3 | 6 (CDXs) | n.d. | n.d. | 7 | |||||||
| H8T8 | Chondrosarcoma | 48 | m | TNM: ypT4 ypNX L0 V0 Pn0 R0 (UICC 2017 [8th Edition]) | resection, dorsal thigh | 3× Doxorubicin/Ifosfamide; radiotherapy | 20 | 4 | 2 | 2 | 11 | 1 | 3 ‡ | 11 |
| I0A0 | Ewing Sarcoma | 20 | f | Stage: IV | metastasectomy of pulmonary metastasis | 6× VIDE, 3× VAI; 4× Temoz./Irinot./Vinc., 1× ICE, 1× VAI; irradiation of the lung; 3× Temoz./Irinot.; 6× Topot./Cycloph. | 13 | 1 | 5 | 1 | 6 | n.d. | n.d. | 5 |
| I7N42 | DSRCT | 21 | f | TNM: Tx N0 M1 (REN, PER) Stage: IV (UICC 2016 [8th Edition]) |
resection of pulmonary primarius | 3× VIDE | 4 | 0 | 0 | 1 | 3 | n.d. | n.d. | 1 |
| M4M51 | Ewing Sarcoma | 22 | m | TNM: M0 | ascites fluid, recurrent tumor sites: neuroforamina and Os sacrum | 6× VIDE, 8× VAI | 20 | 3 | 4 | 0 | 13 | n.d. | n.d. | 9 |
| M4M53 | 6× VIDE, 8× VAI; 4× Topotecan/Cyclophosphamide | 8 | 0 | 0 | 0 | 8 | 2 | 4 ‡ | 6 | |||||
| MFS-SN1 | Myxofibrosarcoma | 71 | m | TNM (initial): pT2b N0 M1 (PUL) G3 (MX) TNM (current): pT4, pN0(0/3), L0, V0, Pn0, R1, G high-grade |
resection, right adductor approaching femur | resection | 13 | 0 | 1 | 0 | 12 | 2 | 8 ‡ | 10 |
| mLPS-SN1 | Myxoid Liposarcoma | 62 | m | TNM: pT2a/b N0 M1 Stage: IV (UICC 2009 [7th Edition]) |
abdominal tumor debulking, Omentum and Colon Transversum | resection, 3× Doxorubicin/Ifosfamide; laparotomy, Ixoten, Trabectidin, Eribulin |
10 | 0 | 0 | 0 | 10 | 2 | 7 ‡ | 9 |
| MPNST-SN1 | MPNST | 66 | f | TNM: rT0 N0 M1 pulm, per Stage: IV (UICC 2016 [8th Edition]) |
metastasis, small intestine section | radiotherapy | 6 | 2 | 0 | 1 | 3 | n.d. | n.d. | n.d. |
| Y0L5 | Ewing Sarcoma | 20 | f | TNM: cT2 N0 M0 Stage: IIB (UICC 2016 [8th Edition]) |
resection, left femur | 5× VDC, 4× IE; Denosumab | 14 | 2 | 6 | 1 | 5 | n.d. | n.d. | 4 |
| EW-7 | Ewing Sarcoma | 20 * | f * | n.a. | derived from metastatic site: Pleural effusion * | n.a. | 44 | 13 | 3 | 0 | 28 | n.d. | n.d. | 5 |
| TC-32 | Ewing Sarcoma | 17 * | f * | n.a. | derived from sampling site: Bone; left ilium * | n.a. | 99 | 12 | 1 | 4 | 82 | 0 | 10 | 10 |